Allergan's ubrogepant meets in Phase III for acute migraine

Allergan plc (NYSE:AGN) said ubrogepant (MK-1602) met the co-primary endpoints in the Phase III ACHIEVE I trial for the acute treatment of migraine. The company expects data this half from the Phase III ACHIEVE II trial of ubrogepant

Read the full 389 word article

User Sign In